Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ethinylestradiol→

Ethinylestradiol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57-63-6
Molecular formula
C20H24O2
Molecular weight
296.4034 g/mol
Drug class
Synthetic oestrogenestrogen receptor agonist
Mechanism of action
Activates estrogen receptors, regulating transcription of oestrogen-responsive genes and suppressing gonadotropin secretion through hypothalamic-pituitary feedback. Most contemporary use is in fixed combinations with a progestogen.
Indications / reported uses
  • Component of combined hormonal contraceptive products for prevention of pregnancy
  • Used in selected hormone-replacement or other endocrine indications only in authorised fixed combinations; do not attribute the full indication of a combination product to ethinylestradiol monotherapy

Sources: NHS — Combined hormonal contraception · NLM MeSH — Ethinylestradiol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ethinylestradiol Environmental Risk Assessment (ERA) (the Ethinylestradiol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.